This talk addresses prevention of stroke in patients with atrial fibrillation and the prevention and treatment of venous thromboembolism. Dr. Ruff discusses the enhanced AF risk stratification tools to assess an individual patient’s risk of stroke and bleeding and compares the relative efficacy and safety of the new anticoagulants (NOACs) with warfarin. He also reviews the management of patients with venous thromboembolism, both prevention in high-risk hospitalized patients and the treatment of patients who present with an acute DVT or PE. Learn about the different anticoagulant strategies available and review the factors that impact the duration of treatment.

Learning Objectives

  • Implement appropriate risk stratification for patients with AF
  • Assess the risks and benefits of oral anticoagulation options for stroke prevention in patients with AF
  • Select and initiate an appropriate anticoagulant strategy for patients at risk for recurrent VTE
  • Identify high-risk medical patients for whom thromboprophylaxis should be initiated

Faculty Disclosures

The following financial relationships have been disclosed by faculty.

Christian T. Ruff, MD, MPH

Research Support from Daiichi Sankyo. Consultant for Boehringer Ingelheim Pharmaceuticals, Inc and Daiichi Sankyo. Advisory Board for Boehringer Ingelheim Pharmaceuticals, Inc and Daiichi Sankyo.


Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

Commercial Supporters

Not Applicable

Education Partners

Not Applicable


Not Applicable

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.